Institut de Génétique Humaine, CNRS UPR1142, Montpellier, France.
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):529-35. doi: 10.1097/QAI.0b013e3181f25bab.
For unclear reasons, about 50% of HIV-infected subjects harbour CXCR4-using (X4) viral strains in addition of CCR5-using (R5) viral strains at late stages of the disease. One hypothesis is that a low CD4(+) T-cell surface CCR5 density could facilitate the emergence of X4 strains. Alternatively, one could argue that a high CD4(+) T-cell surface CXCR4 density that is observed in individuals presenting with X4 strains, could favour R5 to X4 switch. Here, we tested both hypotheses. In vivo, we observed by quantitative flow cytometry no difference in CD4(+) T-cell surface CCR5 densities between patients with or without X4 strains. In the course of an in vitro R5 infection, the delay of emergence of X4 mutants was similar between cells expressing 2 distinct cell surface CCR5 densities, but shorter (12 ± 0 days and 21 ± 0 days, respectively, P = 0.01) in cells expressing a high surface CXCR4 density as compared with cells with a low surface CXCR4 density. These data argue for a role of CXCR4 density, but not of CCR5 density, in the emergence of X4 strains. They are reassuring concerning the risk of inducing an R5 to X4 switch using CCR5 antagonists to treat HIV infection.
由于不明原因,约 50%的 HIV 感染者在疾病晚期除了 CCR5 利用(R5)病毒株外,还存在 CXCR4 利用(X4)病毒株。一种假设是,低 CD4(+)T 细胞表面 CCR5 密度可能促进 X4 株的出现。或者,可以认为在表现出 X4 株的个体中观察到的高 CD4(+)T 细胞表面 CXCR4 密度可能有利于 R5 向 X4 的转换。在这里,我们检验了这两种假设。在体内,我们通过定量流式细胞术观察到,有或没有 X4 株的患者之间,CD4(+)T 细胞表面 CCR5 密度没有差异。在体外 R5 感染过程中,表达两种不同表面 CCR5 密度的细胞中,X4 突变体出现的延迟相似,但表达高表面 CXCR4 密度的细胞比表达低表面 CXCR4 密度的细胞短(分别为 12 ± 0 天和 21 ± 0 天,P = 0.01)。这些数据表明 CXCR4 密度而不是 CCR5 密度在 X4 株的出现中起作用。这对于使用 CCR5 拮抗剂治疗 HIV 感染以诱导 R5 向 X4 转换的风险是令人放心的。